Sign in
Taking people in United StatesPhase 4

Studies how cystic fibrosis drugs work in children and genetic factors

Tests elexacaftor, ivacaftor and tezacaftor in children with cystic fibrosis.

Key facts

Who runs it
Arkansas Children's Hospital Research Institute
Where
Birmingham, Little Rock, and Seattle, United StatesSee the 3 sites
Trial code
Registry title
Ensuring Access to Optimal Therapy in CF: The ENACT Study
Status
Recruiting
Phase
Phase 4
People taking part
100 people, planned
Started
10 Jun 2025
Expected to end
Dec 2030
Type of study
Interventional
Treatments tested
  • Elexacaftor / Ivacaftor / Tezacaftor
  • therapeutic drug monitoring
Record updated
2 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and adults with cystic fibrosis who already take a stable triple combination CFTR modulator treatment and whose lung disease is stable.

Age
The inclusion criteria say 2 years and older; the registry lists a minimum age of 3 Years.
Sex
All sexes can join.
Disease stage
Cystic fibrosis confirmed by CFF diagnostic criteria. Lung disease must be clinically stable: no documented acute drop in FEV1 of more than 10%, and no extra antibiotics (IV or oral) within 4 weeks before screening.
Earlier treatment
Must have been on a stable dose of triple combination CFTR modulator therapy for at least two weeks before Visit 1.
Biomarker or test result
Known CFTR genotype is required.

Main reasons for not taking part

  • Recent significant unintentional weight loss in the 4 weeks before screening
  • Pregnant or breastfeeding
  • Alcohol or substance abuse in the 6 months before screening
  • Took part in a study with an investigational treatment within 28 days (or 5 half-lives, whichever is longer) before screening
  • Medical or psychiatric illness or other conditions that would interfere with taking part, in the investigator's opinion

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • documentation of CF diagnosis per CFF diagnostic criteria and known CFTR genotype
  • age 2 years and older
  • ability to provide written informed consent and/or assent (by subject and/or legal guardian)
  • on a stable dose of triple combination CFTR modulator therapy for at least two weeks prior to Visit 1
  • clinically stable lung disease, defined as no documented acute decrease in FEV1 > 10%, OR use of additional antibiotics (intravenous [IV] or oral [PO]) within 4 weeks prior to screening

Who cannot take part

  • recent significant unintentional weight loss, as determined by the investigator, in the 4 weeks prior to screening
  • history of alcohol or substance abuse in the 6 months prior to screening
  • participation in a study involving an investigational intervention within 28 days (or 5 half-lives, whichever is longer) prior to screening
  • in the opinion of the Investigator, medical or psychiatric illness, or other conditions that would interfere with participation
  • pregnant or breastfeeding female

Where in United States

  • The University of Alabama at BirminghamBirmingham, United StatesContact: Stefanie Krick, MDTaking people
  • Arkansas Children's HospitalLittle Rock, United StatesContact: Michelle Gillespie, Research CoordinatorTaking people
  • University of WashingtonSeattle, United StatesContact: Kathleen Ramos, MDTaking people

About the trial

What the trial wants to find out

This clinical trial is examining the action and effects of several new drugs in the treatment of cystic fibrosis in children. In addition, several genetic factors are examined. The hope is that the ability to determine prior to treatment those individuals who will or will not respond to existing therapies will avoid needless risk of side effects and the high cost of a potentially ineffective treatment regimen. Understanding the way these drugs work in the body and the best way to study them is critical to expanding the use of these drugs to all patients with cystic fibrosis (CF).

The group in the trial

  • Single ArmOther group

    Participants may be enrolled in an observational one-visit study for association of concentration with side effects. Participants may proceed to a single arm study if they have side effects to assess the feasibility of adjusting dose to maintain concentrations within an estimated effective range. Once within the range, dosing is no longer adjusted. Side effects will be evaluated as described in the protocol.

    Treatment: Elexacaftor / Ivacaftor / Tezacaftor and therapeutic drug monitoring

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Ensuring Access to Optimal Therapy in Cystic Fibrosis: The ENACT Study
Plain-language title
Studies how cystic fibrosis drugs work in children and genetic factorsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
2 June 2026